Panacea Life Sciences HoldingsPLSH Return-on-Tangible-Equity is 0.00% as of Sep. 2025. The stock has 6 warning signs investors should review. Among 896 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 99.89% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Panacea Life Sciences Holdings's annualized net income for the quarter that ended in Sep. 2025 was $-0.74 Mil. Panacea Life Sciences Holdings's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $-3.09 Mil. Therefore, Panacea Life Sciences Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was N/A%.
The historical rank and industry rank for Panacea Life Sciences Holdings's Return-on-Tangible-Equity or its related term are showing as below:
PLSH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3530.12 Med: -119.02 Max: -103.42
Current: Negative Tangible Equity
During the past 4 years, Panacea Life Sciences Holdings's highest Return-on-Tangible-Equity was -103.42%. The lowest was -3,530.12%. And the median was -119.02%.
PLSH's Return-on-Tangible-Equity is ranked better than 99.89% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs PLSH: Negative Tangible Equity
Panacea Life Sciences Holdings (OTCPK:PLSH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Panacea Life Sciences Holdings Return-on-Tangible-Equity Related Terms
Panacea Life Sciences Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Return-on-Tangible-Equity Chart
PLSH vs NPHC, OWPC, CBDY: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Panacea Life Sciences Holdings (PLSH) has a Return-on-Tangible-Equity of 0.00% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #1 out of 896 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Panacea Life Sciences Holdings' Return-on-Tangible-Equity too high?
Panacea Life Sciences Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Panacea Life Sciences Holdings ranks #1 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' Return-on-Tangible-Equity compare to NPHC and OWPC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #1 out of 896 companies for Return-on-Tangible-Equity. This places Panacea Life Sciences Holdings in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Return-on-Tangible-Equity is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Business Description
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 